The FDA approved Adamas Pharmaceuticals Inc’s treatment for a side effect caused by a commonly prescribed Parkinson’s drug.
Ohio’s Department of Insurance said non-profit managed care company CareSource will sell health plans in Paulding County in 2018 – the last county in the United States that would have been without Obamacare individual coverage during the year.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology (ISPE) announced their plans for a one-day conference focused on real-world evidence.
Novel Gene Therapy Shows Three-Fold Improvement in Recurrence-Free Survival in High-Risk, Early-Stage Bladder Cancer Patients Where Current Gold-Standard Treatment Fails
The Society of Urologic Oncology and the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) announced that the Journal of Clinical Oncology published results from a Phase II clinical study led by the SUO-CTC demonstrating the potential effectiveness of Instiladrin (rAD-IFN/Syn3) in patients with high grade, BCG refractory or relapsed Non-Muscle Invasive Bladder Cancer.
Financial concerns continue to plague ImmunoCellular Therapeutics as the company continues to look for cost-cutting measures that will provide enough resources to fund continued R&D on the company’s Stem-to-T-Cell research program.
AstraZeneca’s blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data.
Novartis AG’s Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer.
Swiss pharma group Roche said the U.S. Food and Drug Administration granted priority review to its emicizumab for hemophilia A with inhibitors.
GSW, an INC Research/inVentiv Health company and industry leader in healthcare advertising, named Sonja Foster-Storch as President. Foster-Storch reports to Lisa Stockman, President of inVentiv Health Communications.
Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.